Methicillin-resistant Staphylococcus aureus (MRSA)
infection is a grave concern in
burn-injured patients. We investigated the efficacy of
interleukin-18 (IL-18) treatment in postburn MRSA
infection. Alternate-day
injections of
IL-18 into
burn-injured C57BL/6 mice significantly increased their survival after MRSA
infection and after
methicillin-sensitive S. aureus
infection. Although
IL-18 treatment of
burn-injured mice augmented natural
IgM production before MRSA
infection and
gamma interferon (IFN-γ) production after MRSA
infection, neither
IgM nor IFN-γ significantly contributed to the improvement in mouse survival.
IL-18 treatment increased/restored the serum
tumor necrosis factor (TNF),
IL-17,
IL-23,
granulocyte colony-stimulating factor (
G-CSF), and
macrophage inflammatory protein (MIP-2) levels, as well as the neutrophil count, after MRSA
infection of
burn-injured mice; it also improved impaired neutrophil functions, phagocytic activity, production of
reactive oxygen species, and MRSA-killing activity. However,
IL-18 treatment was ineffective against MRSA
infection in both
burn- and
sham-injured neutropenic mice. Enhancement of neutrophil functions by
IL-18 was also observed in vitro. Furthermore, when neutrophils from IL-18-treated
burn-injured mice were adoptively transferred into nontreated
burn-injured mice 2 days after MRSA challenge, survival of the recipient mice increased. NOD-SCID mice that have functionally intact neutrophils and macrophages (but not T, B, or NK cells) were substantially resistant to MRSA
infection.
IL-18 treatment increased the survival of NOD-SCID mice after
burn injury and MRSA
infection. An adoptive transfer of neutrophils using NOD-SCID mice also showed a beneficial effect of IL-18-activated neutrophils, similar to that seen in C57BL/6 mice. Thus, although neutrophil functions were impaired in
burn-injured mice,
IL-18 therapy markedly activated neutrophil functions, thereby increasing survival from postburn MRSA
infection.